Global Non-Melanoma Skin Cancer Market Size, Status, Research and Forecast 2019-2025

Published On: Aug 2019

Format: PDF

Publisher: QY Research

Pages: 109

Report ID: 48278

Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages but if not treated properly, it can quickly mushroom and spread to other body parts.
Radiation therapy has a market share approaching 88% in the non-melanoma skin cancer treatment market in 2017 itself and is unlikely to cede this commanding position anytime soon.
In 2018, the global Non-Melanoma Skin Cancer market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Non-Melanoma Skin Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Non-Melanoma Skin Cancer development in United States, Europe and China.

The key players covered in this study
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Roche
Merck
Novartis
Mylan
Sun Pharmaceutical
Almirall
Elekta
Varian Medical Systems
Sensus Healthcare
iCAD
Accuray
Ion Beam Applications

Market segment by Type, the product can be split into
Chemotherapy
Radiation Therapy
Photodynamic Therapy

Market segment by Application, split into
Hospitals
Clinics
Ambulatory Surgical Centers
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Non-Melanoma Skin Cancer status, future forecast, growth opportunity, key market and key players.
To present the Non-Melanoma Skin Cancer development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Non-Melanoma Skin Cancer are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Non-Melanoma Skin Cancer Market Size Growth Rate by Type (2014-2025)
1.4.2 Chemotherapy
1.4.3 Radiation Therapy
1.4.4 Photodynamic Therapy
1.5 Market by Application
1.5.1 Global Non-Melanoma Skin Cancer Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Non-Melanoma Skin Cancer Market Size
2.2 Non-Melanoma Skin Cancer Growth Trends by Regions
2.2.1 Non-Melanoma Skin Cancer Market Size by Regions (2014-2025)
2.2.2 Non-Melanoma Skin Cancer Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Non-Melanoma Skin Cancer Market Size by Manufacturers
3.1.1 Global Non-Melanoma Skin Cancer Revenue by Manufacturers (2014-2019)
3.1.2 Global Non-Melanoma Skin Cancer Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Non-Melanoma Skin Cancer Market Concentration Ratio (CR5 and HHI)
3.2 Non-Melanoma Skin Cancer Key Players Head office and Area Served
3.3 Key Players Non-Melanoma Skin Cancer Product/Solution/Service
3.4 Date of Enter into Non-Melanoma Skin Cancer Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Non-Melanoma Skin Cancer Market Size by Type (2014-2019)
4.2 Global Non-Melanoma Skin Cancer Market Size by Application (2014-2019)

5 United States
5.1 United States Non-Melanoma Skin Cancer Market Size (2014-2019)
5.2 Non-Melanoma Skin Cancer Key Players in United States
5.3 United States Non-Melanoma Skin Cancer Market Size by Type
5.4 United States Non-Melanoma Skin Cancer Market Size by Application

6 Europe
6.1 Europe Non-Melanoma Skin Cancer Market Size (2014-2019)
6.2 Non-Melanoma Skin Cancer Key Players in Europe
6.3 Europe Non-Melanoma Skin Cancer Market Size by Type
6.4 Europe Non-Melanoma Skin Cancer Market Size by Application

7 China
7.1 China Non-Melanoma Skin Cancer Market Size (2014-2019)
7.2 Non-Melanoma Skin Cancer Key Players in China
7.3 China Non-Melanoma Skin Cancer Market Size by Type
7.4 China Non-Melanoma Skin Cancer Market Size by Application

8 Japan
8.1 Japan Non-Melanoma Skin Cancer Market Size (2014-2019)
8.2 Non-Melanoma Skin Cancer Key Players in Japan
8.3 Japan Non-Melanoma Skin Cancer Market Size by Type
8.4 Japan Non-Melanoma Skin Cancer Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Non-Melanoma Skin Cancer Market Size (2014-2019)
9.2 Non-Melanoma Skin Cancer Key Players in Southeast Asia
9.3 Southeast Asia Non-Melanoma Skin Cancer Market Size by Type
9.4 Southeast Asia Non-Melanoma Skin Cancer Market Size by Application

10 India
10.1 India Non-Melanoma Skin Cancer Market Size (2014-2019)
10.2 Non-Melanoma Skin Cancer Key Players in India
10.3 India Non-Melanoma Skin Cancer Market Size by Type
10.4 India Non-Melanoma Skin Cancer Market Size by Application

11 Central & South America
11.1 Central & South America Non-Melanoma Skin Cancer Market Size (2014-2019)
11.2 Non-Melanoma Skin Cancer Key Players in Central & South America
11.3 Central & South America Non-Melanoma Skin Cancer Market Size by Type
11.4 Central & South America Non-Melanoma Skin Cancer Market Size by Application

12 International Players Profiles
12.1 Boehringer Ingelheim
12.1.1 Boehringer Ingelheim Company Details
12.1.2 Company Description and Business Overview
12.1.3 Non-Melanoma Skin Cancer Introduction
12.1.4 Boehringer Ingelheim Revenue in Non-Melanoma Skin Cancer Business (2014-2019)
12.1.5 Boehringer Ingelheim Recent Development
12.2 Bristol-Myers Squibb
12.2.1 Bristol-Myers Squibb Company Details
12.2.2 Company Description and Business Overview
12.2.3 Non-Melanoma Skin Cancer Introduction
12.2.4 Bristol-Myers Squibb Revenue in Non-Melanoma Skin Cancer Business (2014-2019)
12.2.5 Bristol-Myers Squibb Recent Development
12.3 Eli Lilly
12.3.1 Eli Lilly Company Details
12.3.2 Company Description and Business Overview
12.3.3 Non-Melanoma Skin Cancer Introduction
12.3.4 Eli Lilly Revenue in Non-Melanoma Skin Cancer Business (2014-2019)
12.3.5 Eli Lilly Recent Development
12.4 Roche
12.4.1 Roche Company Details
12.4.2 Company Description and Business Overview
12.4.3 Non-Melanoma Skin Cancer Introduction
12.4.4 Roche Revenue in Non-Melanoma Skin Cancer Business (2014-2019)
12.4.5 Roche Recent Development
12.5 Merck
12.5.1 Merck Company Details
12.5.2 Company Description and Business Overview
12.5.3 Non-Melanoma Skin Cancer Introduction
12.5.4 Merck Revenue in Non-Melanoma Skin Cancer Business (2014-2019)
12.5.5 Merck Recent Development
12.6 Novartis
12.6.1 Novartis Company Details
12.6.2 Company Description and Business Overview
12.6.3 Non-Melanoma Skin Cancer Introduction
12.6.4 Novartis Revenue in Non-Melanoma Skin Cancer Business (2014-2019)
12.6.5 Novartis Recent Development
12.7 Mylan
12.7.1 Mylan Company Details
12.7.2 Company Description and Business Overview
12.7.3 Non-Melanoma Skin Cancer Introduction
12.7.4 Mylan Revenue in Non-Melanoma Skin Cancer Business (2014-2019)
12.7.5 Mylan Recent Development
12.8 Sun Pharmaceutical
12.8.1 Sun Pharmaceutical Company Details
12.8.2 Company Description and Business Overview
12.8.3 Non-Melanoma Skin Cancer Introduction
12.8.4 Sun Pharmaceutical Revenue in Non-Melanoma Skin Cancer Business (2014-2019)
12.8.5 Sun Pharmaceutical Recent Development
12.9 Almirall
12.9.1 Almirall Company Details
12.9.2 Company Description and Business Overview
12.9.3 Non-Melanoma Skin Cancer Introduction
12.9.4 Almirall Revenue in Non-Melanoma Skin Cancer Business (2014-2019)
12.9.5 Almirall Recent Development
12.10 Elekta
12.10.1 Elekta Company Details
12.10.2 Company Description and Business Overview
12.10.3 Non-Melanoma Skin Cancer Introduction
12.10.4 Elekta Revenue in Non-Melanoma Skin Cancer Business (2014-2019)
12.10.5 Elekta Recent Development
12.11 Varian Medical Systems
12.12 Sensus Healthcare
12.13 iCAD
12.14 Accuray
12.15 Ion Beam Applications

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details